Neuronetics, Inc. · NASDAQ:STIM
Neuronetics — Canaccord Genuity 44th Annual Growth Conference 2024
16 slides from Neuronetics's conference presentation, Aug 14, 2024
Slide 1: Canaccord Genuity 44th Annual Growth Conference
Canaccord Genuity 44th Annual Growth Conference NASDAQ: STIM August 14, 2024 Now FDA-Cleared as an Add-on Therapy for Ages 15 and Older! Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the “Company”) relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a n
Slide 3: No Offer or Solicitation
No Offer or Solicitation This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities,
Slide 4: Presenters
38+ years of experience Keith Sullivan President & Chief Executive Officer Presenters Steve Furlong Executive Vice President, Chief Financial Officer & Treasurer 37+ years of experience neurostar.com
Slide 5: NeuroStar is Renewing Lives by Transforming Neurohealth
NeuroStar is Renewing Lives by Transforming Neurohealth Market Leader in TMS #1 Physician recommended with over 6.6 million treatment sessions performed in over 182,000 patients Robust R&D Pipeline 3rd generation system. Largest clinical dataset in the world to drive new indications Widely Reimburse
Slide 6: Significant, Underpenetrated U.S. TMS Market Opportunity
Significant, Underpenetrated U.S. TMS Market Opportunity Patients suffering from depression, depression with anxiety, and OCD3 >29 million 10.9 million Patients currently being treated4,5 4.4 million Poorly served by medication4,7,8 Patients treated using TMS9 ~100 thousand 0.4% Penetration U.S. Adu
Slide 7: Core Initiatives Driving Growth
Core Initiatives Driving Growth Delivering Better Patient Care Through the Better Me Provider Program* Improved Response Times 6.4x Improvement in 24-Hour Follow Up (compared to non-BMP sites) Education Through NSU 61% Increase in Patients Treated (compared to sites who have not attended) Addressing
Slide 8: FY 2024 Guidance
FY 2024 Guidance Metric Guidance Range Third Quarter Revenue $18.5 - $19.5 M Full Year Revenue $78.0 - $80.0 M (unchanged) Full Year Operating Expenses $78.0 - $80.0 M (unchanged)
Slide 9: Neuronetics + Greenbrook TMS
Neuronetics + Greenbrook TMS Combining two of the nation’s largest mental health companies to create an organization with the ability to leverage its scale and capabilities to treat more patients suffering from mental health conditions
Slide 10: Greenbrook TMS Overview
Greenbrook TMS Overview Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the U.S. for the treatment of mental health disorders > 47,000 Unique patients treated to date > 1,520,000 Treatments administered to date $73.8 M FY 2023 Revenue ~120 Treatment Centers i
Slide 11: Transaction Rationale
Transaction Rationale Creates a vertically integrated organization capable of providing access to mental health treatment with significant scale in the U.S. Increased brand awareness for NeuroStar More consistent delivery of best practices at Greenbrook sites Ability to provide customers with traini
Slide 12: Creates Benefits for All of Neuronetics' Customers
Creates Benefits for All of Neuronetics’ Customers Increases brand recognition for NeuroStar to educate more patients Expands training opportunities on how to incorporate med management, Spravato, and NeuroStar into practices Potential to improve customer business operations through: Access to natio
Slide 13: Attractive Financial Profile
Attractive Financial Profile Increased Revenue Scale and Strong Growth Profile 2023 FY Combined Revenue of ~$145 Million Anticipate mid-teens revenue growth in fiscal years 2025 and 2026 Material Cost Synergies ~$15M of annual cost savings, majority of which to be realized in fiscal 2025 Accelerated
Slide 14: Q&A
Q&A
Slide 15: References
References Sackeim HA, et al. (2020) J. Affect. Disord. 277:65-74. Based on a real-world, retrospective study using CGI-S and a sample size of 615 patients. Dunner DL, et al. (2014). J Clin Psychiatry. 75(12):1394-1401 Data on file, Neuronetics, Inc. NIMH https://www.nimh.nih.gov/health/statistics/m
Slide 16: Neuronetics
_s/ Neurostary
Neuronetics — Canaccord Genuity 44th Annual Growth Conference 2024 on 6ix